Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 30:2018:5367814.
doi: 10.1155/2018/5367814. eCollection 2018.

The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats

Hongcai Cai  1   2 , Guowei Zhang  1 , Zechen Yan  3 , Xuejun Shang  1
Affiliations

The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats

Hongcai Cai et al. Evid Based Complement Alternat Med. .

Abstract

Benign prostatic hyperplasia (BPH) is common among elderly men, of which inflammation, oxidative stress, proliferative, and apoptotic changes play important roles. Xialiqi (XLQ) capsule, a traditional Chinese herbal formula, is used as a potential drug in treating BPH. This study aims to evaluate the therapeutic effect of XLQ capsule on testosterone propionate- (TP-) induced BPH in rats. Fifty male Sprague-Dawley rats were randomly divided into 5 groups: sham control, BPH model, high and low dose of XLQ, and finasteride as a positive control group. All groups were treated with appropriate drugs/normal saline for 28 consecutive days. Prostate weights were recorded; histopathological changes and content of IL-8, TNF-α, DHT, SOD, MDA, caspase-3, and PCNA of the prostate were determined. Animals with BPH demonstrated significantly increased prostate weights and prostate index, higher levels of IL-8, TNF-α, DHT, MDA, and PCNA, but lower activity of SOD and reduced expression of caspase-3. After treatment with XLQ, significant reductions of prostate weights, prostate index, IL-8, TNF-α, DHT, MDA, and PCNA, increased activity of SOD, and higher level of caspase-3 were shown. The present study indicates that XLQ can effectively prevent the development of TP-induced BPH model through mechanisms of anti-inflammation, antioxidation, antiproliferation, and proapoptosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of XLQ on the histopathological appearance of the prostate, prostate weight, body weight, and prostate index of BPH rats. (a) Effects of XLQ on prostate weight, body weight, and prostate index. (b) Effects of XLQ on the histopathological appearance of the prostate. Up: hematoxylin and eosin (H&E) staining ×200; down: H&E staining ×400. ∗: versus the sham operation control group, P<0.01; Δ: versus the model of BPH group, P<0.01; #: versus the high-dose XLQ group, P<0.01; ▲: versus the low-dose XLQ group, P<0.01. Error bars indicate SEM.
Figure 2
Figure 2
Effects of XLQ on the expression levels of IL-8, TNF-α, DHT, and PCNA in BPH rats. (a) Effects of XLQ on the expression levels of IL-8, TNF-α in the serum, and prostate of BPH rats. (b) Effects of XLQ on the expression levels of DHT in the serum and prostate of BPH rats. (c) Effects of XLQ on the expression of PCNA in the prostate of BPH rats. IHC: immunohistochemistry. ∗: versus the sham operation control group, P<0.01; Δ: versus the model of BPH group, P<0.01; #: versus the high-dose XLQ group, P<0.01; ▲: versus the low-dose XLQ group, P<0.01. Error bars indicate SEM.
Figure 3
Figure 3
Effects of XLQ on the activity of SOD, concentration of MDA, and expression level of caspase-3 in BPH rats. (a) Effects of XLQ on the activity of SOD and concentration of MDA in the serum and prostate of BPH rats. (b) Effects of XLQ on the expression of caspase-3 in the prostate of BPH rats. Magnification: ×200. ∗: versus the sham operation control group, P<0.01; Δ: versus the model of BPH group, P<0.01; #: versus the high-dose XLQ group, P<0.01; ▲: versus the low-dose XLQ group, P<0.01. Error bars indicate SEM.
See this image and copyright information in PMC

References

    1. Gacci M., Corona G., Salvi M., et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994–1003. - PubMed
    1. Patel N. D., Parsons J. K. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian Journal of Urology. 2014;30(2):170–176. doi: 10.4103/0970-1591.126900. - DOI - PMC - PubMed
    1. Atawia R. T., Tadros M. G., Khalifa A. E., Mosli H. A., Abdel-Naim A. B. Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats. Toxicology Letters. 2013;219(2):160–169. doi: 10.1016/j.toxlet.2013.03.002. - DOI - PubMed
    1. Zheng H., Xu W., Lin J., Peng J., Hong Z. Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis. Molecular Medicine Reports. 2013;7(3):848–854. doi: 10.3892/mmr.2013.1265. - DOI - PubMed
    1. Jang H., Bae W.-J., Yuk S.-M., et al. Seoritae Extract Reduces Prostate Weight and Suppresses Prostate Cell Proliferation in a Rat Model of Benign Prostate Hyperplasia. Evidence-Based Complementary and Alternative Medicine. 2014;2014:7. doi: 10.1155/2014/475876.475876 - DOI - PMC - PubMed